Our latest articles
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.
39% of the patients assessed carried this biomarker, the conference presentation reveals.
Clinical data back Claudin18.2 as a target for treating stomach cancer – but biomarker diagnosis is needed.
Readout of Tropion-Lung01, testing the most advanced indication for datopotamab, could lead to a first-half US filing.
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.